Compounds and compositions as protein kinase inhibitors
US7569593B2 · kind B2 · utility
5Cited by
3References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 1, 2004 |
| Grant date | Aug 4, 2009 |
| Priority date | — |
| Expiry date | Oct 26, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D405/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, PDGF-R, lck, SAPK2α, p38, TGFβ, KDR, c-Kit, b-RAF, c-RAF, FLT1 and FLT4 kinases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.